Kenvue
Kenvue Inc.
Key figures
Period 2024-12-30 to 2025-12-28ConsolidatedU.S. GAAP
RevenueDisclosed
US$15.1B
Operating marginCalculated
16.0%
Net assets to total assetsCalculated
39.8%
Company profile
Tables scroll sideways
Disclosed data
Profitability
★★★★☆position among all companies
16.0%
Growth (revenue, 4-year average)
★★☆☆☆position among all companies
0.1%
Capital efficiency
★★★☆☆position among all companies
13.7%
Revenue and profit
Performance, financial position and capital allocation
Kenvue
Recent performance trends
Kenvue
Cash flow trends
Consolidated indicators (9 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$15.1 billion | US$14.9 billion | US$15.4 billion | US$15.5 billion | US$15.1 billion |
| Operating income | US$2.9 billion | US$2.7 billion | US$2.5 billion | US$1.8 billion | US$2.4 billion |
| Net income | US$2.1 billion | US$2.1 billion | US$1.7 billion | US$1.0 billion | US$1.5 billion |
| Total assets | Could not be retrieved | US$27.3 billion | US$27.9 billion | US$25.6 billion | US$27.1 billion |
| Shareholders' equity | US$20.5 billion | US$20.0 billion | US$11.2 billion | US$9.7 billion | US$10.8 billion |
| Net cash provided by (used in) operating activities | US$0.3 billion | US$2.5 billion | US$3.2 billion | US$1.8 billion | US$2.2 billion |
| Net cash provided by (used in) investing activities | US$-0.2 billion | US$-0.4 billion | US$-0.5 billion | US$-0.4 billion | US$-0.4 billion |
| Net cash provided by (used in) financing activities | US$0 | US$-1.6 billion | US$-2.5 billion | US$-1.6 billion | US$-1.8 billion |
| Cash and cash equivalents | Could not be retrieved | US$1.2 billion | US$1.4 billion | US$1.1 billion | US$1.1 billion |
Revenue scale in the same industry
Kenvue
Chemicals and pharmaceuticals: 56 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Johnson & JohnsonFY Dec 2025 US$94.2B
- 2 Procter & GambleFY Jun 2026 US$87.0B
- 3 ELI Lilly ANDFY Dec 2025 US$65.2B
- … 11 companies
- 15 EcolabFY Dec 2025 US$16.1B
- 16 PPG IndustriesFY Dec 2025 US$15.9B
- 17 KenvueThis companyFY Dec 2025 US$15.1B
- 18 THE Estee Lauder CompaniesFY Jun 2026 US$15.0B
- 19 Regeneron PharmaceuticalsFY Dec 2025 US$14.3B
- … 37 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$0.5 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$1.1 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$-1.8 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-0.4 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$2.2 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$0.6 billion | Consolidated | Disclosed |
| Dividends paid | US$1.6 billion | Consolidated | Disclosed |
| Net assets | US$10.8 billion | Consolidated | Disclosed |
| Net sales | US$15.1 billion | Consolidated | Disclosed |
| Operating income | US$2.4 billion | Consolidated | Disclosed |
| Net income | US$1.5 billion | Consolidated | Disclosed |
| Total assets | US$27.1 billion | Consolidated | Disclosed |
| Purchase of treasury stock | US$0.2 billion | Consolidated | Disclosed |
| Operating margin | 16.0% | Consolidated | Calculated |
| Net assets to total assets | 39.8% | Consolidated | Calculated |
| Net margin | 9.7% | Consolidated | Calculated |
| Return on equity | 13.7% | Consolidated | Calculated |